Cargando…

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters

Diabetes is defined by hyperglycaemia due to progressive insulin resistance and compromised insulin release. In parallel, alpha cells develop dysregulation of glucagon secretion. Diabetic patients have insufficient glucagon secretion during hypoglycaemia and a lack of inhibition of glucagon secretio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armour, Sarah L., Frueh, Alexander, Knudsen, Jakob G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882857/ https://www.ncbi.nlm.nih.gov/pubmed/35237171 http://dx.doi.org/10.3389/fphar.2022.837664

Ejemplares similares

Glucose Controls Glucagon Secretion by Regulating Fatty Acid Oxidation in Pancreatic α-Cells
por: Armour, Sarah L., et al.
Publicado: (2023)

Dysregulation of Glucagon Secretion by Hyperglycemia-Induced Sodium-Dependent Reduction of ATP Production
por: Knudsen, Jakob G., et al.
Publicado: (2019)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Jing, Yuling, et al.
Publicado: (2022)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
por: Ye, Yangli, et al.
Publicado: (2019)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
por: Sun, He, et al.
Publicado: (2023)

Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
por: Chen, Lu, et al.
Publicado: (2020)

Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Hemoglobin Levels: A Meta-analysis of Randomized Controlled Trials
por: Qu, Wei, et al.
Publicado: (2021)

Role of sodium‐glucose transporters in glucose uptake of the intestine and kidney
por: Harada, Norio, et al.
Publicado: (2012)

Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
por: Kalra, Sanjay, et al.
Publicado: (2015)

Transient Receptor Potential Vanilloid 1 Activation Enhances Gut Glucagon-Like Peptide-1 Secretion and Improves Glucose Homeostasis
por: Wang, Peijian, et al.
Publicado: (2012)

An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats
por: He, Lili, et al.
Publicado: (2022)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
por: Li, Chun Xing, et al.
Publicado: (2023)

A Description of Acute Renal Failure and Nephrolithiasis Associated With Sodium–Glucose Co-Transporter 2 Inhibitor Use: A VigiBase Study
por: Frent, Ioana, et al.
Publicado: (2022)

The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis
por: Kandeel, Mahmoud
Publicado: (2022)

Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism
por: Tan, Yunke, et al.
Publicado: (2021)

Sodium–Glucose Cotransporter 2 Inhibitors Work as a “Regulator” of Autophagic Activity in Overnutrition Diseases
por: Fukushima, Kazuhiko, et al.
Publicado: (2021)

Decreased expression of Glucagon-like peptide-1 receptor and Sodium-glucose co-transporter 2 in patients with proliferative diabetic retinopathy
por: Chen, Hui, et al.
Publicado: (2022)

The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies
por: Meier, Alexandra, et al.
Publicado: (2018)

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
por: Mascolo, Annamaria, et al.
Publicado: (2023)

Sodium-glucose co-transporter 2 inhibitors beyond diabetes
por: Williams, Dimity L, et al.
Publicado: (2022)

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
por: D'Onofrio, Nunzia, et al.
Publicado: (2021)

Sodium-Glucose Co-Transporter 2 Inhibitors Use Improves the Satisfaction With Anti-diabetic Agent Treatment: A Questionnaire-based Propensity Score-matched Study
por: Shi, Fang-Hong, et al.
Publicado: (2022)

Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis
por: Tian, Lei, et al.
Publicado: (2022)

Appraisal of Non-Cardiovascular Safety for Sodium–Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials
por: Shi, Fang-Hong, et al.
Publicado: (2019)

Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Dabravolski, Siarhei A., et al.
Publicado: (2022)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Phloridzin inhibits high K(+)-induced contraction via the inhibition of sodium: glucose cotransporter 1 in rat ileum
por: KANDA, Hidenori, et al.
Publicado: (2017)

Protein Kinases Mediate Anti-Inflammatory Effects of Cannabidiol and Estradiol Against High Glucose in Cardiac Sodium Channels
por: Fouda, Mohamed A., et al.
Publicado: (2021)

Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion
por: Parker, H. E., et al.
Publicado: (2012)

The expression and survival significance of sodium glucose transporters in pancreatic cancer
por: Du, Jiali, et al.
Publicado: (2022)

Sodium glucose co-transport 2 inhibitors for gout treatment
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2022)

Medication counselling with sodium glucose transporter 2 inhibitor therapy
por: Kalra, Sanjay, et al.
Publicado: (2014)

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
por: Kalra, Sanjay, et al.
Publicado: (2015)

Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020)

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
por: Erythropoulou-Kaltsidou, Anastasia, et al.
Publicado: (2019)

Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study
por: Lee, Yen-Chieh, et al.
Publicado: (2022)

Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy
por: Ren, Changzhen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kav5tl2vsm84sc0cqebrpub1l1